Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Exploratory Phase II Study of Trastuzumab Rezetecan in Combination With Retlirafusp Alfa ± Pertuzumab as Neoadjuvant Therapy for Locally Advanced HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07716111 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.

NCT NCT07716111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07716111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Exploratory Phase II Study of Trastuzumab Rezetecan in Combination With Retlirafusp Alfa ± Pertuzumab as Neoadjuvant Therapy for Locally Advanced HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 16, 2026
Completion date
August 31, 2029
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric or gastroesophageal junction adenocarcinoma